Ameristat Pharmaceuticals, Inc.   

 

Sutent - sutent@aipharma.com

SUTENT® (sunitinib malate) is a new, oral, multikinase inhibitor for patients with advanced renal cell carcinoma (RCC),* and gastrointestinal stromal tumor (GIST) after disease progression on, or intolerance to, imatinib mesylate.

More information is available at www.sutent.com